Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Monkasho Holds Symposium on National Bioresources Project
July 22, 2002
- WORLD NEWS IN BRIEF
July 22, 2002
- Tsumura Studying Combination of Western, Oriental Medicine
July 15, 2002
- PhRMA Adopts Principles for Conduct of Clinical Trials
July 15, 2002
- E2B/M2 Trial Results Announced
July 15, 2002
- Bayer BP to Start Hemophilia Awards Program
July 15, 2002
- MCC Acquires IC-Vec of UK Engaged in Gene Therapy
July 15, 2002
- Diabetic Nephropathy Approved as New Indication of Irbesartan
July 15, 2002
- Nippon Kayaku to Invest in Reverse Proteomics Research Institute
July 15, 2002
- Losartan Reduces Risk of Cardiovascular Death, Disease
July 15, 2002
- BUSINESS NEWS IN BRIEF
July 15, 2002
- Bayer BP Reports Possibility of Removal of Pathogenic Human Prion Protein
July 15, 2002
- AstraZeneca Decides to Provide Iressa before Listing
July 15, 2002
- RELOCATION
July 15, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 15, 2002
- Esmolol, Ferucarbotran Recommended for Approval
July 15, 2002
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 15, 2002
- WEBSITE NEWS
July 15, 2002
- Generics of 162 Active Ingredients Included in NHI Price List
July 15, 2002
- Press Seminar
July 15, 2002
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…